Apellis announced a corporate reconstructing to drive growth of Syfovre and Empaveli, which will include cost-cutting initiatives expected to save the company up to $300 million through 2024, according to a press release.
“We are taking important actions to strengthen our ability to invest in growth opportunities and support the company's long-term success, including maximizing the significant opportunity with Syfovre,” Cedric Francois, MD, PhD, co-founder and CEO of Apellis, said in the release. “As a more focused organization, we believe these initiatives put Apellis in a